key: cord-0798788-vpomgedg authors: Rokni, Mohsen; Ghasemi, Vida; Tavakoli, Zahra title: Immune responses and pathogenesis of SARS‐CoV‐2 during an outbreak in Iran: Comparison with SARS and MERS date: 2020-04-08 journal: Rev Med Virol DOI: 10.1002/rmv.2107 sha: 8df7dc1b5d44c3f4348de7938d44d6eaa73854f4 doc_id: 798788 cord_uid: vpomgedg The beginning of 2020 has seen the emergence of COVID‐19, an outbreak caused by a novel coronavirus, SARS‐CoV‐2, an important pathogen for humans. There is an urgent need to better understand this new virus and to develop ways to control its spread. In Iran, the first case of the COVID‐19 was reported after spread from China and other countries. Fever, cough, and fatigue were the most common symptoms of this virus. In worldwide, the incubation period of COVID‐19 was 3 to 7 days and approximately 80% of infections are mild or asymptomatic, 15% are severe, requiring oxygen, and 5% are critical infections, requiring ventilation. To mount an antiviral response, the innate immune system recognizes molecular structures that are produced by the invasion of the virus. COVID‐19 infection induces IgG antibodies against N protein that can be detected by serum as early as day 4 after the onset of disease and with most patients seroconverting by day 14. Laboratory evidence of clinical patients showed that a specific T‐cell response against SARS‐CoV‐2 is important for the recognition and killing of infected cells, particularly in the lungs of infected individuals. At present, there is no specific antiviral therapy for COVID‐19 and the main treatments are supportive. In this review, we investigated the innate and acquired immune responses in patients who recovered from COVID‐19, which could inform the design of prophylactic vaccines and immunotherapy for the future. Tehran University of Medical Sciences and Health Services, Grant/Award Number: 12354 The beginning of 2020 has seen the emergence of COVID-19, an outbreak caused by a novel coronavirus, SARS-CoV-2, an important pathogen for humans. There is an urgent need to better understand this new virus and to develop ways to control its spread. In Iran, the first case of the COVID-19 was reported after spread from China and other countries. Fever, cough, and fatigue were the most common symptoms of this virus. In worldwide, the incubation period of COVID-19 was 3 to 7 days and approximately 80% of infections are mild or asymptomatic, 15% are severe, requiring oxygen, and 5% are critical infections, requiring ventilation. To mount an antiviral response, the innate immune system recognizes molecular structures that are produced by the invasion of the virus. COVID-19 infection induces IgG antibodies against N protein that can be detected by serum as early as day 4 after the onset of disease and with most patients seroconverting by day 14. Laboratory evidence of clinical patients showed that a specific T-cell response against SARS-CoV-2 is important for the recognition and killing of infected cells, particularly in the lungs of infected individuals. At present, there is no specific antiviral therapy for COVID-19 and the main treatments are supportive. In this review, we investigated the innate and acquired immune responses in patients who recovered from COVID-19, which could inform the design of prophylactic vaccines and immunotherapy for the future. was reported in Iran and other countries, and transmission rate, mortality rate and the clinical manifestation slowly emerged. 5 In Iran on 19 March 2020, a total of 18 407 confirmed cases were reported with an apparent fatality rate of 6.98% ( Figure 1 ). As a result, approximately 0.02% of the Iranian population is affected by coronavirus disease. This index is currently at about 0.01% for China and less than 0.01% for Japan. However, Iran is less affected than Spain and Italy, according to official data from the WHO. and ORF1b (open reading frames) is used for direct production of two polypeptides: polyprotein 1a/1ab (pp1a/pp1ab), which encodes nonstructural proteins (nsps). 6 ORFs on the one-third of the genome near the 3'terminus encode at least four main structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins 6, 7 (Figure 2A ). The phylogenetic tree shows that the virus undergoes immunologic pressure and can increase the frequency of mutations in the genetic sequence of coronavirus among people from different countries. This process can increase viral virulence and transmissibility 8 ( Figure 2B ). In worldwide, based on hospitalized patient data, the incubation period of SARS-CoV-2 was 3 to 7 days and approximately 80% of infections are mild or asymptomatic, 15% are severe, requiring oxygen, and 5% are critical infections, requiring ventilation. 9 Fever, cough, and fatigue were the most common symptoms. 10 The spike protein receptor-binding domain (RBD) predicts that SARS-CoV-2 may use angiotensin-converting enzyme 2 (ACE2) as a host cell receptor for infection in human airway epithelia that is the most commonly damaged organ. 11, 12 It is still unknown if SARS-CoV-2 infects any immune cells because only a small percentage of lung resident monocytes/macrophages express the ACE2 receptor. It is possible that other receptors may exist, or another cellular entry mode is utilized such as antibody-dependent enhancement. 13 Many studies related to COVID-19 suggest a protective role of both cell-mediated and humoral immune responses in humans. 14, 15 The S protein and the N protein of SARS-CoV-2 were the most immunogenic and abundantly expressed proteins during infection. 15 In a study in China, most patients developed lymphopenia and pneumonia with characteristic pulmonary ground-glass opacity changes on a chest CT scan that was gold standard in diagnostic. Other changes that were usually observed in patients of this study included: lymphopenia 1100 μ/L (45%), increased serum IL-6 (58%), and increased C-reactive protein (99%) were detected. Neutrophilia and lymphocytopenia also correlated with disease severity and mortality. 2, 19 To mount an antiviral response, the innate immune system recognizes molecular structures that are produced by the invasion of the virus, promote the production of type I interferon (IFN-α and IFN-β), which are important for antiviral innate immune responses and able to suppress viral replication and dissemination at an early stage. 22, 23 This process can cause complications such as exhaustion, weakness, and cough in patients. 24 The important point is, for SARS-CoV-2, the response to viral infection by type I IFN is suppressed (Figure 3 ). Humoral immune response, especially the production of neutralizing antibody, plays a protective role by limiting the infection at a later phase and prevents re-infection in the future. 26 SARS-CoV-2 infection induces IgG production against N protein that can be detected by serum as early as day 4 after the onset of disease and with most patients seroconverting by day 14. 27,28 Based on immunofluorescence assays and ELISA, in 89% of the recovered patients, IgG-specific and neutralizing antibodies were detected 2 years after SARS infection. 26, 28, 29 In addition, peak specific IgM on the ninth day after disease and the class switching to IgG in the second week were detected. 27, 29, 30 During the long-term follow-up of survivors, IgG is only detectable in recovered patients at 6 years after SARS infection, 31, 32 suggesting decreasing levels of memory B-cells will also be found against SARS-CoV-2. 31 Laboratory evidence of clinical patients showed that specific T-cell responses against SARS-CoV-2 is important for the recognition and F I G U R E 2 The genomic structure and phylogenetic tree of coronavirus SARS-CoV-2. A, The genome structure of the new coronavirus. B, The phylogenetic tree of representatives from different countries killing of infected cells, particularly in the lungs of infected individuals. 33 The results of a study with 128 cases showed that the number and function of CD8 + T cells were greater than CD4 + T cell responses, 14, 34 although whether the memory T-cell response is sufficient to protect from reinfection needs further study. [34] [35] [36] Furthermore, the virus-specific T cells from the severe infection tended to have a central memory phenotype with a significantly higher frequency of polyfunctional CD4 + T cells with cytokine secretion, for example, IFNγ, TNFα, and IL-2, and CD8 + T cells with cytokine secretion, for example, IFNγ, TNFα and degranulated state, as com- should be 88%-90%. Invasive mechanical ventilation is used as a last resort. 44 The results of a recent study with 100 patients have demonstrated that chloroquine phosphate is more effective than control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative conversion, and shortening the disease course. 45 In addition, teicoplanin, an antibiotic used to treat staphylococci infection, previously has been shown to be effective in inhibiting the first stage of MERS-coronavirus viral cycle in human cells. This activity is conserved on the SARS-CoV-2, thus placing teicoplanin as a potential treatment for patients with this virus. 46 Recently, tocilizumab, also known as atlizumab, prescribed for two patients with COVID-19 infection in Iran and has shown promising results. This drug is an immunosuppressive humanized monoclonal antibody against the interleukin-6 receptor (IL-6R) and mainly used for the treatment of rheumatoid arthritis (RA) and IL-6 is a cytokine that plays an important role in immune response. 18, 47 More studies F I G U R E 3 Host immune responses during SARS-CoV-2 infection. Airborne SARS-CoV-2 leads to infection of ACE2 expressing target cells such as alveolar type 2 cells or other unknown target cells. Cells infected by the virus may escape IFN I resulting in uncontrolled viral replication. The recruitment of neutrophils and monocytes/macrophages is by chemotaxis of pro-inflammatory cytokines. The "CRS" production-specific Th1/Th17 may cause immunopathologic injury in the lung that leads to pneumonia. B cells or plasma cells produce SARS-CoV-2 specific antibodies that may help neutralize viruses. 25 Lymphopenia caused by viral infections such as SARS-CoV-2 can occur with three mechanisms: The first mechanism is the reduction of lymphocyte production or impaired lymphopoiesis. The second mechanism is apoptosis and destruction of lymphocytes. The third mechanism that reduces lymphopenia without decreasing production or increasing degradation is lymphocyte redistribution, such as lymphocyte attachment to the vascular endothelium (a phenomenon similar to neutrophil marginalization) that can lead to decrease in circulating lymphocytes with controls and large sample size are needed to evaluate the effect of this drug on the treatment of COVID-19 symptoms. We reviewed innate and acquired immune responses and the development of immune protection cells of patients who recovered from COVID-19, which could be a starting point for the design of prophylactic vaccines and immunotherapy-based therapy against coronaviruses. In addition, vaccines that stimulate both the cellular and humoral immune response against coronaviruses should also be considered. Review of bats and SARS A new coronavirus associated with human respiratory disease in China Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor Coronavirus disease 2019 (COVID-19): a perspective from China A novel coronavirus outbreak of global health concern The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status COVID-2019: the role of the nsp2 and nsp3 in its pathogenesis Genomic diversity of SARS-CoV-2 in coronavirus disease 2019 patients Clinical features of patients infected with 2019 novel coronavirus in Wuhan A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2 Potential factors influencing repeated SARS outbreaks in China Coronavirus infections and immune responses Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV Clinical characteristics of 82 death cases with COVID-19. medRxiv Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: antiinflammatory strategies Review of the clinical characteristics of coronavirus disease 2019 (COVID-19) SARS and MERS: recent insights into emerging coronaviruses Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Coronavirus Endoribonuclease activity in porcine epidemic diarrhea virus suppresses type I and type III interferon responses The type I IFN-induced miRNA, miR-21 Interaction of SARS and MERS coronaviruses with the antiviral interferon response Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study A pneumonia outbreak associated with a new coronavirus of probable bat origin Multiple organ infection and the pathogenesis of SARS Virusspecific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice T cell responses to whole SARS coronavirus in humans Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARSrecovered patients Characteristics of traveler with Middle East respiratory syndrome Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope Treatment of SARS with human interferons Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? Tocilizumab: a review in rheumatoid arthritis Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS We acknowledge all health care workers involved in the diagnosis (Immunology Lab) and treatment of patients in Buali Hospital, Zahedan University of Medical Sciences. The authors declare that they have no conflict of interest. https://orcid.org/0000-0003-0534-4251